Previous 10 | Next 10 |
2023-12-06 14:31:18 ET More on Simulations Plus Big Pharma's AI Ambitions: The Countdown For Simulations Plus Begins Simulations Plus Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Simulations Plus Historical earnings data for Simulat...
2023-11-15 11:15:00 ET Summary Equity markets declined in Q3 2023 as concerns over higher interest rates and a potential recession grew. Large-cap stocks outperformed small-cap stocks, largely due to the strong performance of mega-cap technology stocks. Conestoga's small-cap g...
Demonstrates How Putting Clients First Drives Growth and Fuels Innovation Reiterates 2024 Guidance Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and eff...
Amparo de la Peña, Vice President of Pharmacometrics at Simulations Plus, will join Jeff Sachs, Pavan Vaddady and Hao Zhu as new board members for 2024 Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and bio...
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it will hold a virtual Investor Day on Tuesday, Novemb...
2023-10-26 13:38:28 ET Summary Simulations Plus reported strong Q4 2023 results, with an 11% YoY revenue growth and a 33% increase compared to the previous quarter. The company's valuation is high compared to its financials and growth prospects, and it faces intense competition fr...
2023-10-25 22:13:08 ET Simulations Plus, Inc. (SLP) Q4 2023 Earnings Conference Call Oct 25, 2023, 05:00 PM ET Company Participants Tamara Gonzales - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial ...
2023-10-25 16:15:31 ET More on Simulations Plus Seeking Alpha’s Quant Rating on Simulations Plus Historical earnings data for Simulations Plus Dividend scorecard for Simulations Plus Financial information for Simulations Plus For further detail...
Fiscal 2023 revenue increased 11% year-over-year to $59.6 million Provides Fiscal 2024 revenue guidance of $66 - $69 million (+10-15%) and EPS guidance of $0.66 - $0.68 Simulations Plus to host its Investor Day on November 14, 2023 Simulations Plus, Inc. (Nasdaq: SLP), a...
St. Joe Company (The) (JOE) is expected to report for Q1 2024 Meta Platforms Inc. (META) is expected to report $3.62 for Q3 2023 Industrial Logistics Properties Trust (ILPT) is expected to report $0.11 for Q3 2023 Mid-America Apartment Communities Inc. (MAA) is expected to report $2.2...
News, Short Squeeze, Breakout and More Instantly...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance an...
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulati...
2024-06-24 16:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...